Press-release for stocks related to enroll

Prices are updated after-hours

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Published: 2021-02-22 (Crawled : 12:03) - globenewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M

| -98.6% | O: -3.56% H: 3.41% C: -8.55%
covid vaccine phase 3 trial enroll

Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis
Published: 2021-01-14 (Crawled : 12:03) - globenewswire.com
ORGO | $2.91 1.75% 1.72% 420K

| -61.99% | O: 32.7% H: 7.9% C: -2.57%
phase 3 trial osteoarthritis enroll designation rmat

ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
Published: 2021-01-07 (Crawled : 12:03) - globenewswire.com
PRQR | News | $1.965 5.65% 5.34% 130K

| -55.4% | O: 0.47% H: 6.78% C: 5.61%
trial treatment enroll

Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Published: 2021-01-06 (Crawled : 12:03) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

| -77.88% | O: 0.0% H: 1.32% C: -4.64%
phase 3 trial enroll

| -60.1% | O: 0.74% H: 8.56% C: 3.91%
trial phase 1b phase 2b enroll pharma

67%

33%

AGBA | News | $1.26 215.0% 68.25% 130M

EGOX | $0.0515 43.06% 30.1% 330M

OLB 4 | $0.33 -14.95% 25.53% 840K

NVFY | $2.77 31.28% 23.83% 33M

ZCMD | $1.87 28.97% 22.46% 31M

RCON | $0.1112 13.01% 21.28% 1.7M

INSG | $3.03 25.21% 20.13% 330K

GCTK | $0.8191 22.25% 18.2% 190K

WLGS | $0.59 18.0% 17.9% 2.3M

ASNS | $0.828 21.75% 17.86% 18K

Save your searches and get alerts when important news are released.